Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
Oral CGRP Inhibitor Is First For Dual Use
Jun 02 2021
•
By
Mandy Jackson
Nurtec was approved for acute treatment of migraine before it was cleared for migraine prevention • Source: Alamy
Keep up with the top pharma business news of the week. On the go.
Scrip brings you a weekly bulletin of top picks.
More from New Products
More from Scrip